These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 24861428)

  • 1. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
    Zhang J; Yu J; Sun X; Meng X
    Cancer Lett; 2014 Aug; 351(1):6-12. PubMed ID: 24861428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
    Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
    Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
    Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
    Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study.
    Fang L; Sun X; Song Y; Zhang Y; Li F; Xu Y; Ma S; Lin N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):873-7. PubMed ID: 26310285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives.
    Berger LA; Riesenberg H; Bokemeyer C; Atanackovic D
    Lung Cancer; 2013 Jun; 80(3):242-8. PubMed ID: 23453646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
    Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
    Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
    Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reaction of plasma adiponectin level in non-small cell lung cancer patients treated with EGFR-TKIs.
    Umekawa K; Kimura T; Kudoh S; Suzumura T; Nagata M; Mitsuoka S; Matsuura K; Oka T; Yoshimura N; Kira Y; Hirata K
    Osaka City Med J; 2013 Jun; 59(1):53-60. PubMed ID: 23909081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure.
    Shukuya T; Takahashi T; Naito T; Kaira R; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Murakami H; Harada H; Mitsuya K; Endo M; Nakasu Y; Takahashi K; Yamamoto N
    Lung Cancer; 2011 Dec; 74(3):457-61. PubMed ID: 21571388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.
    Bartolotti M; Franceschi E; Brandes AA
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1429-35. PubMed ID: 23249107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.
    Jamal-Hanjani M; Spicer J
    Clin Cancer Res; 2012 Feb; 18(4):938-44. PubMed ID: 22167408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.
    Becker A; Crombag L; Heideman DA; Thunnissen FB; van Wijk AW; Postmus PE; Smit EF
    Eur J Cancer; 2011 Nov; 47(17):2603-6. PubMed ID: 21784628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
    Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.
    Yang Z; Guo Q; Wang Y; Chen K; Zhang L; Cheng Z; Xu Y; Yin X; Bai Y; Rabbie S; Kim DW; Ahn MJ; Yang JC; Zhang X
    Sci Transl Med; 2016 Dec; 8(368):368ra172. PubMed ID: 27928026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis.
    Chen Y; Wang M; Zhong W; Zhao J
    Lung Cancer; 2013 Nov; 82(2):313-8. PubMed ID: 24011632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F
    J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
    Chang MH; Ahn HK; Lee J; Jung CK; Choi YL; Park YH; Ahn JS; Park K; Ahn MJ
    Cancer; 2011 Jan; 117(1):143-51. PubMed ID: 20803614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M; He CS; Wei SH; Zhang L
    Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
    Wu JY; Yu CJ; Chang YC; Yang CH; Shih JY; Yang PC
    Clin Cancer Res; 2011 Jun; 17(11):3812-21. PubMed ID: 21531810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.